120 related articles for article (PubMed ID: 3363182)
1. Chronotropic actions of cholecystokinin octapeptide on the rat heart.
Marker JD; Roberts ML
Regul Pept; 1988 Mar; 20(3):251-9. PubMed ID: 3363182
[TBL] [Abstract][Full Text] [Related]
2. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A.
Wiśniewska RJ
Pol J Pharmacol; 1998; 50(3):203-12. PubMed ID: 9861628
[TBL] [Abstract][Full Text] [Related]
3. Effects of cholecystokinin (CCK-33) and its fragments, C-terminal octapeptide (CCK-8) and C-terminal tetrapeptide (CCK-4), on the circulatory system of diabetic rats.
Fiedorowicz RJ; Wiśniewski K
Pol J Pharmacol Pharm; 1989; 41(6):561-72. PubMed ID: 2485904
[TBL] [Abstract][Full Text] [Related]
4. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
Wiśniewska RJ
Pol J Pharmacol; 1998; 50(3):213-23. PubMed ID: 9861629
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat.
Gaw AJ; Hills DM; Spraggs CF
Br J Pharmacol; 1995 Jun; 115(4):660-4. PubMed ID: 7582487
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
[TBL] [Abstract][Full Text] [Related]
7. The effect of cholecystokinin (CCK-33) and C-terminal fragments of cholecystokinin: CCK-8 and CCK-4 on the cardiovascular system in rats.
Wiśniewska RJ; Wiśniewski K
Gen Pharmacol; 1996 Jan; 27(1):159-63. PubMed ID: 8742514
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
Millington WR; Mueller GP; Lavigne GJ
J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
[TBL] [Abstract][Full Text] [Related]
9. Interaction of cholecystokinin (CCK-8) with agonist and antagonist of beta-adrenergic receptors in circulatory system of diabetic rats.
Wiśniewska RJ; Wiśniewski K
Pol J Pharmacol; 1996; 48(3):293-7. PubMed ID: 9112665
[TBL] [Abstract][Full Text] [Related]
10. Effects of C-terminal fragments of cholecystokinin on exocrine and endocrine secretion from isolated perfused rat pancreas.
Okabayashi Y; Otsuki M; Ohki A; Sakamoto C; Baba S
Endocrinology; 1983 Dec; 113(6):2210-15. PubMed ID: 6196184
[TBL] [Abstract][Full Text] [Related]
11. The excitatory effect of cholecystokinin on rat neostriatal neurons: ionic and molecular mechanisms.
Wu T; Wang HL
Eur J Pharmacol; 1996 Jun; 307(2):125-32. PubMed ID: 8832213
[TBL] [Abstract][Full Text] [Related]
12. Endogenous CCK depresses contractile activity within the ascending myenteric reflex pathway of rat ileum.
Storr M; Sattler D; Hahn A; Schusdziarra V; Allescher HD
Neuropharmacology; 2003 Mar; 44(4):524-32. PubMed ID: 12646289
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: studies on the structure-activity relationship.
Sandberg E; Ahrén B; Tendler D; Efendic S
Pharmacol Toxicol; 1988 Jul; 63(1):42-5. PubMed ID: 3041399
[TBL] [Abstract][Full Text] [Related]
14. The interaction of cholecystokinin and its fragments with norepinephrine in the circulatory system of diabetic rats.
Fiedorowicz RJ; Wiśniewski K
Pol J Pharmacol Pharm; 1989; 41(6):573-83. PubMed ID: 2577226
[TBL] [Abstract][Full Text] [Related]
15. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.
Rex A; Barth T; Voigt JP; Domeney AM; Fink H
Neurosci Lett; 1994 May; 172(1-2):139-42. PubMed ID: 8084519
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors.
Hill RG; Hughes J; Pittaway KM
Neuropharmacology; 1987 Apr; 26(4):289-300. PubMed ID: 3295578
[TBL] [Abstract][Full Text] [Related]
17. Effects of cholecystokinin octapeptide on the exocrine pancreas in a new rat model of type 2 diabetes.
Kuntz E; Pinget M; Damgé C
Eur J Pharmacol; 2002 Jul; 448(2-3):253-61. PubMed ID: 12144949
[TBL] [Abstract][Full Text] [Related]
18. Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME.
Hoły Z; Wiśniewski K
Rocz Akad Med Bialymst; 1998; 43():250-70. PubMed ID: 9972062
[TBL] [Abstract][Full Text] [Related]
19. [The role of cholecystokinin octapeptide (CCK-8) in regulating thyrotropin secretion in rats. In vivo studies].
Krowicki ZK; Sadowska-Krowicka H
Endokrynol Pol; 1989; 40(3):133-41. PubMed ID: 2627920
[TBL] [Abstract][Full Text] [Related]
20. Effects of cholecystokinin-related peptides on retention of passive avoidance behaviour.
Fekete M; Penke B; Telegdy G
Acta Physiol Acad Sci Hung; 1982; 60(4):237-42. PubMed ID: 6314742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
